RT Journal Article
SR Electronic
T1 Dysregulated immunity in SARS-CoV-2 infected pregnant women
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.13.20231373
DO 10.1101/2020.11.13.20231373
A1 Sherer, Morgan L.
A1 Lei, Jun
A1 Creisher, Patrick
A1 Jang, Minyoung
A1 Reddy, Ramya
A1 Voegtline, Kristin
A1 Olson, Sarah
A1 Littlefield, Kirsten
A1 Park, Han-Sol
A1 Ursin, Rebecca L.
A1 Ganesan, Abhinaya
A1 Boyer, Theresa
A1 Brown, Diane M.
A1 Walch, Samantha N.
A1 Antar, Annukka A. R.
A1 Manabe, Yukari C.
A1 Jones-Beatty, Kimberly
A1 Golden, William Christopher
A1 Satin, Andrew J.
A1 Sheffield, Jeanne S.
A1 Pekosz, Andrew
A1 Klein, Sabra L.
A1 Burd, Irina
YR 2020
UL http://medrxiv.org/content/early/2020/11/16/2020.11.13.20231373.abstract
AB Importance The effects of SARS-CoV-2 infection on immune responses during pregnancy have not been systematically evaluated.Objective To assess the impact of SARS-CoV-2 infection during pregnancy on inflammatory and humoral responses in maternal and fetal samples and compare antibody responses to SARS-CoV-2 among pregnant and non-pregnant women.Design Immune responses to SARS-CoV-2 were analyzed using samples from pregnant and non-pregnant women who had either tested positive or negative for SARS-CoV-2. We measured, proinflammatory and placental cytokine mRNAs, neonatal Fc receptor (FcRn) receptor expression, and tetanus antibody transfer in maternal and cord blood samples. Additionally, we measured anti-spike (S) IgG, anti-S-receptor binding domain (RBD) IgG, and neutralizing antibody (nAb) responses to SARS-CoV-2 in serum or plasma collected from non-pregnant women, pregnant women, and cord blood.Setting Johns Hopkins Hospital (JHH)Participants Pregnant women were recruited through JHH outpatient obstetric clinics and the JHH Labor & Delivery unit. Non-pregnant women were recruited after receiving outpatient SARS-CoV-2 testing within Johns Hopkins Health System, USA. Adult non-pregnant women with positive RT-PCR results for SARS-CoV-2, within the age range of 18-48 years, were included in the study.Exposures SARS-CoV-2Main Outcomes and Measures Participant demographic characteristics, antibody titers, cytokine mRNA expression, and FcRn receptor expression.Results SARS-COV-2 positive pregnant women expressed more IL1β, but not IL6, in blood samples collected within 14 days versus > 14 days after a confirmed SARS-CoV-2 test, with similar patterns observed in the fetal side of placentas, particularly among asymptomatic pregnant women. Pregnant women with confirmed SARS-CoV-2 infection also had reduced anti-S-RBD IgG titers and were less likely to have detectable nAb as compared with non-pregnant women. Although SARS-CoV-2 infection did not disrupt FcRn expression in the placenta, maternal transfer of nAb was inhibited by SARS-CoV-2 infection during pregnancy.Conclusions and Relevance SARS-CoV-2 infection during pregnancy was characterized by placental inflammation and reduced antiviral antibody responses, which may impact the efficacy of COVID-19 therapeutics in pregnancy. The long-term implications of placental inflammation for neonatal health also requires greater consideration.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NIH/NICHD R01HD097608 (IB and SK), NIH/NICHD R21HD099000 (IB), NIH/NCI U54CA260492 (SK), NIH/NIAID HHSN272201400007C (AP), and NIH/NIAID T32AI007417 (MS, RU).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Johns Hopkins IRB approved collection of samples from all patients in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are contained in the manuscript.